04.25.24 -- Impacts Of The Inflation Reduction Act

Dive into the biopharmaceutical realm, where the synthesis of biologically derived APIs encompasses cell line development, fermentation, and sophisticated purification techniques. Outsourced Pharma Capacity Update’s new PARTNER WEEK will include a session featuring CDMOs with capacity for meeting the production demands of your Large Molecule Drug Substance and Development projects. Join this digital event happening May 21st.

Soft sensors can enable real-time monitoring of key process variables, including viable cell density. Here's how one team at Takeda put them to use.

Learn how following strict laboratory practices and conducting routine testing for Mycoplasma contamination using nucleic acid-based assays can help ensure the production of safe and high-quality biopharmaceutical products.

Antibody-based therapeutics are increasing in popularity. Analyze the hurdles of antibody development and manufacturing and explore exciting developments.

Determining ideal media composition for a bacteria is critical because it fosters a satisfactory grow rate, allowing the bacteria to reach the required growth yield.

Explore how to approach the transition of migrating from a vial to a syringe or cartridge, the necessary compatibility testing, and the stresses on the bulk product during formulation and filling.

Learn about the critical role plunger stoppers play in determining a combination drug product's exposure to extractables and leachables.

Explore some of the more challenging aspects surrounding in-use testing for parenteral delivery along with potential strategies to address these issues.

The accuracy and robustness of the technical package an organization submits to its development and/or manufacturing partner are critical to meeting fill project timelines.

Complex next generation biological molecules are becoming increasingly prevalent in today’s biopharmaceutical manufacturing landscape. Through case studies, this webinar will highlight innovative analytical strategies designed to address common challenges occurring during development of new molecular formats such as chain assembly, multiple-MoAs and diverse post-translational modifications. Click here to learn more.

At AGC Biologics, we have developed over 200 mammalian, bacteria and yeast-based processes, giving us the insight necessary to identify and optimize process parameters that are critical for achieving a high-quality, cost-effective manufacturing process.

We are your one integrated partner with the expertise to get your therapeutic product to market faster, helping you accelerate, simplify, and de-risk your biologics.

Delve into how this partner's scalable packaging services for logistics support can achieve higher operational efficiency and lower quality and safety risks.